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Abstract
Cleft lip and/or palate (CL/P) is a common congenital 
malformation with a complex etiology which is not fully 
elucidated yet. Epidemiological studies point to differ-
ent etiologies in the cleft lip and palate subgroups, iso-
lated cleft lip (CL), isolated cleft palate (CP) and com-
bined cleft lip and palate (CLP). In order to understand 
the biological basis in these cleft lip and palate sub-
groups better we studied the expression profiles in hu-
man tissue from patients with CL/P. In each of the CL/P 
subgroups, samples were obtained from three patients 
and gene expression analysis was performed. More-
over, selected differentially expressed genes were an-
alyzed by quantitative RT-PCR, and by immunohisto-
chemical staining of craniofacial tissue from human 
embryos. Osteopontin (SPP1) and other immune re-
lated genes were significantly higher expressed in pal-
ate tissue from patients with CLP compared to CP and 
immunostaining in palatal shelves against SPP1, che-
mokine receptor 4 (CXCR4) and serglycin (PRG1) in hu-
man embryonic craniofacial tissue were positive, sup-
porting a role for these genes in palatal development. 
However, gene expression profiles are subject to varia-
tions during growth and therefore we recommend that 
future gene expression in CL/P studies should use tis-
sue from the correct embryonic time and place if possi-
ble, to overcome the biases in the presented study.
Keywords: cleft lip and palate; congenital abnormal-
ities; gene expression profiling; osteopontin; serglycin
Introduction
Cleft lip and/or palate (CL/P) is a common conge-
nital malformation affecting approximately 2 per 
1000 newborns worldwide (Murray, 2002) and cau-
sing a major psychosocial and economic burden for 
the families. Gaining insight into the etiology of CL/P 
is important as it may lead to improved diagnosis, 
counselling and perhaps preventive measures in the 
future. Although CL/P is a complex disease caused 
by both environmental and genetic factors, most 
studies point to genetic factors as the major de-
terminants (Christensen and Mitchell, 1996). Re-
cently, several genes implicated in CL/P have been 
identified (Jugessur and Murray, 2005), but they can 
only account for a fraction of the etiology. 
    Moreover, epidemiological studies point to that 
CL/P subgroups may have different etiologies, as 
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                                          Affy fold QPCR COGENE Accession Chromosomal Biological Gene                 change fold Affy/number locus functions (CLP vs. CP) change SAGE 
CD14 antigen NM_000591 5q31.3 Phagocytosis, apoptosis, 2.14 A/P
 cell surface receptor linked 
 signal transduction
Serglycin (PRG1) J03223, 10q21.3                    - 2.12- N.A./A
 NM_002727  2.48
Immunoglobulin M87790, 22q11.22 Immune response, 18.90- P/P
  lambda constant 2  AA680302,  antigen binding  19.62
 AV698647
Osteopontin/secreted M83248 4q22.1 Ossification, anti-apoptosis, 4.46 5.3 P/P
 phosphoprotein 1  inflammatory response,  (P＜. 05)
 (SPP1)  cell adhesion and signalling,
 leukocyte chemotaxis, T-helper
 1 type immune response
Chemokine receptor 4 AF348491, 2q21.3 Lymphocyte migration, 1.92- 2.0 A/P
 (CXCR4)  AJ224869  nonmuscle myosin binding,  2.93  (P＜ .05)
 co-receptor for T-cell line-
 adapted human immuno-
 deficiency virus type 1
Adenosine AI916249 1p13.3 Purine nucleotide 1.67 1.9 A/P
 monophosphate  metabolism, AMP  (P＜ .05)
 deaminase 2  deaminase activity
 (isoform L)
 (AMPD2)
Regeneration AI671186 11p13                    - -2.07 N.A./A
 associated muscle
 protease
Hypothetical protein S55735/ 14q32.33 Immune response, antigen 4.67- N.A./P
 MGC27165 and  AJ239383  binding (function from IGHG1  11.19
 gb:AJ239383  and IGHA1)
Immunoglobulin AW575927, 2p11.2 Immune response, 9.46- N.A./P
 kappa constant  BC005332,  antigen binding  11.05
 BG485135,
 M63438
Likely ortholog of rat BF674052 17q23.1                    - 2.65 N.A./P
 vacuole membrane
 protein 1
Hypothetical protein AI190160 17q23.2                    - 6.13 N.A./A
 LOC124773
Accessions numbers are from the Affymetrix GeneChip analysis. 
Functions are from the functions of the human proteins listed in Gene Ontology (GO), http://www.geneontology.org/.
The COGENE database was searched for expression in the relevant tissues (see Methods section) in Affymetrix chip analyses and SAGE libraries, A, ab-
sent; P, present; N.A., not available. A SAGE tag had to be identified twice or more to be considered present.
Table 1. Differently expressed genes (P＜ .05) on Affymetrix GeneChip in palate tissue from patients with cleft palate only (CP) 
versus palate tissue from patients with cleft lip and palate (CLP), selected genes validated by QPCR. 
isolated cleft palate (CP) and combined cleft lip 
and palate (CLP) seldom occur in the same fami-
lies (Fogh-Andersen, 1942), and isolated cleft lip 
(CL) and CLP display different sex ratios and 
prevalences of associated malformations (Harville 
et al., 2005). 
    To gain more insight into the genetic etiology of 
CL/P we studied expression profiles in lip and 
palate tissue from patients with different types of 
orofacial cleft: CL, CP and CLP, rationalizing that 
the epidemiological differences may reflect diffe-
rences in the underlying molecular processes. 
Results
Affymetrix GeneChip analysis
We identified 11 genes which were differentially 
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       Affy fold QPCR COGENE Accession Chromosomal Biological Gene                change fold Affy/number locus functions (CLP vs. CL) change SAGE 
Bone marrow stromal NM_004335 19p13.11 Humoral immune response, -2.11 -2.1, ns A/P
 cell antigen 2 (BST2)  cell proliferation and
 signalling, development
SMART/ HDAC1 ass. AL524033 1p36.13                     - -1.90 -1.2, ns N.A./P
 repressor protein
 (SPEN)
Deiodinase, U53506 14q31.1 Thyroid hormone  -2.49 -1.6, ns A/P
 iodothyronine  generation, 
 type II (DIO2)  selenium binding
Cytochrome c oxidase NM_001864 19q13.12 Cytochrome-c -2.02 N.A./A
 subunit VIIa polypeptide  oxidase activity
 1 (COX7A1)
Butyrophilin, subfamily NM_006994 6p22.1                     - -1.70 A/A
 3, member A3 
 (BTN3A3)
Table 2. Differently expressed genes (P＜ .05) on Affymetrix GeneChip in lip tissue, from patients with cleft lip only (CL) versus lip 
tissue from patients with cleft lip and palate (CLP), selected genes validated by QPCR (ns is non-significant). 
expressed in the palate tissue from CP and CLP 
respectively: CD14 antigen, Serglycin (PRG1), Im-
munoglobulin lambda constant 2, Osteopontin/ 
secreted phosphoprotein 1 (SPP1), Chemokine re-
ceptor 4 (CXCR4), Adenosine monophosphate dea-
minase 2 (isoform L) (AMPD2), Regeneration asso-
ciated muscle protease, Hypothetical protein MGC-
27165, Immunoglobulin kappa constant, Likely or-
tholog of rat vacuole membrane protein 1, Hypo-
thetical protein LOC124773 (Table 1).
    We identified 19 genes differentially expressed 
in the lip tissue from CL and CLP respectively: Bone 
marrow stromal cell antigen 2 (BST2), SMART/ 
HDAC1 associated repressor protein (SPEN), Deio-
dinase, iodothyronine type II (DIO2), Cytochrome c 
oxidase subunit VIIa polypeptide 1 (COX7A1), 
Butyrophilin, subfamily 3, member A3 (BTN3A3), 
Crystallin, alpha B (CRYAB), gb:M27487, gb:AA-
770596, Major histocompatibility complex, class II, 
DQ alpha 2 (HLA-DQA1), Heat shock protein, 
alpha-crystallin-related, B6 (HSPB6), Protein kinase 
C and casein kinase substrate in neurons 3 
(PACN3), EGF-like-domain, multiple 6 (EGFL6), 
Calsequestrin 1 (CASQ1), gb:AF116709, Nuclear 
factor I/X (CCAAT-binding transcription factor) 
(NFIX), Kinase interacting stathmin (UHMK1), Hy-
pothetical protein (CMYA1), Hypothetical protein 
MGC34032, EH domain binding protein 1-like 1 
(EHBP1L1) (Table 2). 
QPCR
While the GeneChip results from the palate tissue 
were verified by QPCR (Table 1), the results from 
the lip tissue could not be verified as it only 
showed a non-significant trend (Table 2), and 
therefore we focus on the results from the palate 
tissue in the following discussion.
Immunohistochemistry
One important bias in our study is that the tissue 
samples investigated are not from the foetal period 
where the development of the lip and palate takes 
place but from fully developed children aged 4-16 
months. To investigate if the genes identified in the 
GeneChip analysis were also expressed during 
human development, we performed immunohisto-
chemical staining in craniofacial tissue from human 
embryos (6th to 11th week of gestation). Immu-
nostainings against the selected proteins osteo-
pontin (SPP1), chemokine receptor 4 (CXCR4) and 
serglycin (PRG1) in frontal sections showed a cha-
racteristic, and in many respects complementary 
expression during initial growth and elevation of 
the palatal shelves (corresponding to 6-8 ges-
tational weeks, Figure 1A and B), and during fusion 
of the palatal processes and removal of the medial 
edge epithelium at the site of fusion (corresponding 
to 9-11 gestational weeks, Figure 1C and D). 
PRG1 protein expression was only present during 
the palatal fusion and medial edge epithelium 
breakdown (Figure 1E). Together, this indicates 
that all the three chosen genes were present in the 
human palate during fusion and therefore may play 
a role in normal palate development.
80    Exp. Mol. Med. Vol. 41(2), 77-85, 2009
       Affy fold QPCR COGENE Accession Chromosomal Biological Gene                change fold Affy/number locus functions (CLP vs. CL) change SAGE 
Crystallin, alpha B AF007162 11q23.1 Protein folding, muscle -2.10 -2.0, ns N.A./A
 (CRYAB)  contraction, visual perception
gb:M27487 M27487 6p21.32 Immune response, integral to -2.13 N.A./A
 (Aligns to  and 6p25.1  plasma membrane
 HLA-DPA1)  (function from HLA-DPA1)
gb:AA770596 AA770596 6q22.1 Cell motility, actin filament -2.06 N.A./P (MARCKS
 (aligns to part  binding (function  from   present in SAGE)
 of MARCKS)  MARCKS)   
Major histocompatibility X00452 6p21.32                      - -3.71 N.A./P
 complex, class II,
 DQ alpha 2
 (HLA-DQA1)
Heat shock protein, AL551046 19q13.12 Protein binding -2.81 N.A./A
 alpha-crystallin-related,
 B6 (HSPB6)
Protein kinase C and NM_016223 11p11.2 Negative regulation of -1.75 1.0, ns N.A./P
 casein kinase substrate  endocytosis, cytoskeletal  (SAGE: 4th 
 in neurons 3 (PACN3)  protein binding  week posterior
 rhombomeres)
EGF-like-domain, NM_015507 Xp22.2                      - -2.65 -1.6, ns N.A./P
 multiple 6 (EGFL6)
Calsequestrin 1 NM_001231 1q23.2                      - -3.02 N.A./A
 (CASQ1)
gb:AF116709 AF116709 11p15.5 H19 (imprinted maternally -1.90 N.A./P (H19 
(Aligns to H19  and 9p24.1  expressed untranslated   present in 
 and JMJD2C)   mRNA) and JMJD2C   SAGE)
 (jumonji domain containing 2C)
Nuclear factor I/X AI817698 19p13.13 Regulation of transcription -2.14 A/A
 (CCAAT-binding
 transcription factor)
 (NFIX)
Kinase interacting AI249980 1q23.3 Amino acid phosphorylation, -1.91 N.A./P
 stathmin (UHMK1)  cell cycle arrest, regulation of
 protein export from nucleus
Hypothetical protein AW755250 3p22.2                      - -2.57 N.A./A
 (CMYA1)
Hypothetical protein AA001450, 1p31.1                      - 2.00- N.A./P
 MGC34032  AW020413  5.08
EH domain binding AK092750 11q13.1                      - -2.08 N.A./A
 protein 1-like 1
 (EHBP1L1)
Accessions numbers are from the Affymetrix GeneChip analysis. 
Functions are from the functions of the human proteins listed in Gene Ontology (GO), http://www.geneontology.org/.
The COGENE database was searched for expression in the relevant tissues (see Methods section) in Affymetrix chip analyses and SAGE libraries, A, ab-
sent; P, present; N.A., not available. A SAGE tag had to be identified twice or more to be considered present.
Table 2. Continued.
In silico analysis
CD14, SPP1, CXCR4, AMPD2 and the immuno-
globulin kappa and lambda constants found in the 
palate tissue were also identified in COGENEs 
Affymetrix and/or SAGE profiles, and our human 
protein interaction network identified a putative 
interaction between SPP1 and PRG1.
    The palate tissue from the two CL/P subgroups 
CP and CLP are also from two different age groups 
(16 and 4 months, respectively). This may intro-
duce a bias to our study, as the differences in gene 
expression may be related to either differences in 
age, CL/P type or both. To circumvent this pro-
blem, we studied the expression of spp1 by QPCR 
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Figure 1. Immunohistochemical staining of human embryonic craniofacial sections. (A) During elevation (6th-8th week embryos) of the palatal shelves os-
teopontin (SPP1) protein is present in the palatal mesenchyme. (B) Chemokine receptor 4 (CXCR4) was present in the epithelial lining of the oronasal 
cavity and the palatal shelves. (C) During fusion (9th-11th week fetuses) of the palatal shelves SPP1 is present in the palatal mesenchyme and (D) 
CXCR4 is present in the epithelium of the oronasal cavity, including the medial edge epithelium, where the palatal shelves meet and fuse. (E) Serglycin 
(PRG1) protein expression was not present in the early gestational age (6-8 weeks), but became apparent during palatal fusion in the epithelial lining of 
the oronasal cavity and in the medial edge epithelium. Black color indicates expression. (Hematoxylin-eosin or toluidine blue staining, primary magnifica-
tion ×1.25).
in wild type mouse palates (three palate samples 
from each of the four age groups; newborn, 1 
week, 1 month and 2 months old, for information 
on cDNA synthesis and primer sequences, see 
Methods), and found an increase in spp1 
expression in 1 week old mouse palates compared 
to the other age groups (results not shown).
Discussion
Expression analysis in human lip and palate tissue 
from patients with different types of cleft lip and 
palate has not been performed before, and epide-
miological studies suggest different etiologies in 
the three CL/P subgroups; CL, CLP and CP (Fogh- 
Andersen, 1942; Harville et al., 2005). Hence, we 
performed the present study in order to obtain 
more information on the genetic etiology of CL/P in 
general and more information on the genetic 
differences in the CL/P subgroups. 
    Ideally, we would have preferred to compare 
expression profiles from patients with CL/P with 
samples from normal children at comparable ages, 
but this was unfortunately not available to us. 
Thus, it is not possible from the present study to 
determine which cleft types have up- or downre-
gulated gene expression patterns compared to 
normal children, merely expression differences 
were detected.
    Our GeneChip analysis identified 11 genes diffe-
rentially expressed in palate tissue from CP and 
CLP (CD14 antigen, PRG1, Immunoglobulin lambda 
constant 2, SPP1, CXCR4, AMPD2, Regeneration 
associated muscle protease, Hypothetical protein 
MGC27165, Immunoglobulin kappa constant, Likely 
ortholog of rat vacuole membrane protein 1, 
Hypothetical protein LOC124773) (Table 1) and 19 
genes differentially expressed in the lip tissue from 
CL and CLP (BST2, SPEN, DIO2, COX7A1, 
BTN3A3, CRYAB, gb:M27487, gb:AA770596, HLA- 
DQA1, HSPB6, PACN3, EGFL6, CASQ1, gb:AF1-
16709, NFIX, UHMK1, CMYA1, Hypothetical pro-
tein MGC34032, EHBP1L1) (Table 2). 
    In the palate tissue all genes, except Regene-
ration associated muscle protease, were higher 
expressed in patients with CLP than CP and in the 
lip tissue all genes, except Hypothetical protein 
MGC34032, were higher expressed in patients with 
CL than CLP. The reason for these skewed results 
is unclear, but a possible explanation may be that 
the genes or some of them are working in a mutual 
biological pathway. 
    While QPCR validated the GeneChip results in 
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palate tissue, QPCR gene expression analysis of 
lip tissue only showed non-significant changes. 
This may indicate that the differences in the 
molecular processes underlying CL and CLP are 
small or at least undetectable by the techniques 
used in our study. Consequently, the following 
discussion will focus on the genes identified as 
differentially expressed in the palate tissue in the 
two CL/P subgroups CLP and CP. 
    Secreted phosphoprotein 1, also referred to as 
osteopontin (SPP1) was expressed at significantly 
higher levels in the palate tissue from the CLP 
patients compared to the CP patients with Gene-
Chip analysis and QPCR, and it was also identified 
in human embryonic palate by immunohistochemi-
stry. Although spp1 transgenic mice do not display 
CL/P (Rittling et al., 1998), SPP1 appears to be a 
promising candidate as SPP1 is involved in ossi-
fication (Jono et al., 2000), and hence potentially 
involved in the formation of bone in the palate. 
Moreover, SPP1 has been emphasized as impor-
tant for palate formation in two recent micro array 
studies on foetal murine palates, which demons-
trated significant changes in expression of SPP1 
during craniofacial development (Brown et al., 
2003; Mukhopadhyay et al., 2004). 
    Our protein interaction network identified a 
putative interaction between SPP1 and Serglycin 
(PRG1) (Rual et al., 2005), another gene diffe-
rentially expressed in palate tissue. PRG1 was 
also identified in immunostainings of human em-
bryonic palate. Our demonstration of PRG1 and 
the recent finding that PRG1 plays a role in the 
ossification process by inhibiting bone mineralization 
in vitro (Theocharis et al., 2006), implicates PRG1 
as a candidate gene for the regulation of normal 
palatal development. 
    Interestingly, several genes with a function in the 
immune system were differentially expressed in 
palate tissue from CLP and CP: CD14 antigen, 
CXCR4, and immunoglobulin kappa and lambda 
constants were all expressed at significantly higher 
levels in palate tissue from CLP patients compared 
to CP (see Table 1 for further information on 
biological functions of the proteins). Immunostai-
nings showed that CXCR4 was present in the 
medial edge epithelium in sections of human em-
bryonic palate, supporting a role for CXCR4 in 
normal palate development.
    The involvement of the immune system in 
relation to CL/P is presently unknown, but animal 
studies support a role for immune related factors in 
craniofacial development: Immune stimulation 
following teratogenic exposure in pregnant mice 
decreased the frequency of foetal abnormalities, 
including cleft palate (Holladay et al., 2002). This 
observed “rescue” of foetal abnormalities was 
considered mediated by TGFβ3, IGFs and ILs 
(Sharova et al., 2002). TGFβ3 is a known immuno- 
modulatory cytokine (Wahl et al., 2004) and is 
considered a CL/P candidate gene based on 
association- and linkage studies and mouse 
models (Murray, 2002). Moreover, previously reco-
gnized CL/P genes have functions related to the 
immune response, most notably, interferon regu-
lating factor 6 (IRF6) (Taniguchi and Takaoka, 
2002; Zucchero et al., 2004) and poliovirus 
receptor-like 1 (PVRL1) (Suzuki et al., 2000; Avila 
et al., 2006). 
    The reason why TGFβ3, IRF6 and PVRL1 were 
not detected in the present study may be that we 
identified differences in expression in the CL/P 
subgroups, so if TGFβ3, IRF6 and PVRL1 have 
similar expression profiles in both CP and CLP, we 
would not identify it.
    Furthermore, an epidemiological study has poin-
ted to an association between maternal infection 
during pregnancy and increased incidence of CL/P 
(Metneki et al., 2005), and together these studies 
suggest a link between the immune system and 
craniofacial development.  
    A cross regulation between bone metabolism 
and the immune system has been identified (Walsh 
et al., 2006), and our findings are suggestive of an 
interaction between the immune response and 
bone metabolism in palate formation, as SPP1 and 
PRG1 are involved in both processes (Jono et al., 
2000; Theocharis et al., 2006; Kolset and Tveit, 
2008). 
    A potential weakness of this study is that the 
expression profiles in the tissue collected and 
analyzed postnatally may not reflect embryonic 
expression, as the cleft-causing processes may 
have ended by the time of analysis. We tried to 
circumvent this problem by performing immuno-
stainings in human embryonic craniofacial tissue 
sections, and detected all the selected proteins 
(SPP1, PRG1 and CXCR4), which support a role 
for these genes in at least normal palate formation. 
However, this does not necessarily indicate that 
these genes play a different role in CP compared 
to CLP, as the palate tissue samples from the CP 
and CLP patients were from different age groups 
(approximately 16 months and 4 months of age, 
respectively), because of differences in the surgical 
protocols. 
    In order to address this age-related problem, we 
studied the expression of spp1 by QPCR in wild 
type mouse palates and found a surge in spp1 
expression in 1 week old mouse palates compared 
to newborn mouse, 1 month and 2 months old 
mouse palates. As CLP is operated earlier than 
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CP, the presence of a similar increase in palatal 
SPP1 in humans during the early neonatal period 
could explain the higher levels of SPP1 in CLP 
compared to CP. 
    In conclusion, by Gene chip analysis and staining 
with selected antibodies in human embryonic pa-
lates, we found supportive evidence that osteopon-
tin (SPP1), chemokine receptor 4 (CXCR4), serg-
lycin (PRG1) and immune related factors may play 
a role in the development of the normal palate, and 
perhaps different roles in the development of the 
cleft palates in CP compared to CLP, although this 
is uncertain due to age differences in the CP and 
CLP subgroups. Our data pointed to an interesting 
cross regulation between immune related factors 
and bone metabolism, a finding which should be 
explored further. 
    A valuable lesson learned from this study is that 
future expression studies in cleft lip and palate 
should preferentially use human foetal tissue with a 
fixed gestational age in order to reduce the 
potential for the biases discussed here.  
Methods
Patients
The study was approved by the local scientific ethics 
committee. Patients with CL, CLP (only the unilateral type) 
or CP only of Caucasian origin were included in the study. 
The patients were examined by the first author (LPJ) and 
were excluded from the study if other visible malformations 
than the CL/P were present. Blood tests or ultrasound 
examinations were not performed. Tissue samples were 
collected during the primary cleft operation, if the parents 
had given their informed written consent. The patients 
were operated by one of three surgeons at the same 
hospital. According to the surgical protocols the children 
with CL and CLP are operated at approximately four 
months of age and CP at approximately 16 months of age. 
    To achieve optimal healing and hence cosmetic and 
functional results, a small piece of mucosa is routinely 
removed during the operation from the borders of the cleft 
region (either lip and/or palate tissue depending on the 
CL/P type). In each of the three CL/P subgroups, samples 
were obtained from three patients. As six tissue samples 
were collected from the CLP patients (three lip and three 
palate tissue samples), the following two types of com-
parisons were possible in the total of 12 samples: Expre-
ssion in lip tissue from patients with CL compared to lip 
tissue from CLP, and expression in palate tissue from CP 
compared to CLP. The mucosa samples from the lips and 
palates are primarily composed of non-keratinized epi-
thelium and sub-epithelial stroma. 
    In embryological terms the lip samples were taken from 
mucosa developed from the maxillary (lateral) prominence 
on the cleft side, not from the frontonasal (median) pro-
minence and samples from the palate were taken from the 
soft palate mucosa at the borders of the cleft. Only one 
sample from either lip and/or palate tissue depending on 
the CL/P type was obtained from each patient. 
Affymetrix GeneChip analysis
Total RNA was extracted from the tissue using the mirVana 
miRNA Isolation Kit (Ambion Inc., Austin, TX). This kit 
provides high quality total RNA and can be used both to 
yield total RNA or RNA enriched for small RNAs, such as 
miRNAs. Initially, we planned to carry out both gene 
expression and miRNA expression in the tissue, but as we 
realized that miRNAs are expressed during embryonic 
development, we declined to perform the miRNA chip 
analysis. The quality and quantity of the extracted total 
RNAs were assessed by agarose gel electrophoresis, 
spectrophotometric ultraviolet (UV) absorbance at 260/280 
nm, and Agilent Bioanalyzer analysis (Agilent Techno-
logies, Inc., Santa Clara, CA). Gene expression was per-
formed on Affymetrix GeneChip Human Genome U133A 
Plus 2.0 Array (Affymetrix, Inc., Santa Clara, CA). Labe-
lling, hybridization, washing and image scanning were 
performed according to the Affymetrix standard protocol: 
Two μg of total RNA was used to synthesise double- 
stranded cDNA with the Superscript Choice system 
(Invitrogen) using an oligo(dT) primer containing a T7 RNA 
polymerase promoter (GenSet). The cDNA was used as 
the template for an in vitro transcription reaction to 
synthesise biotin-labeled antisense cRNA (IVT labelling 
Kit, Affymetrix Inc.). After fragmentation at 94oC for 35 min 
in fragmentation buffer (40 mM Tris, 30 mM magnesium 
acetate, 10 mM potassium acetate), the labeled cRNA was 
hybridised for 16 h to Affymetrix HG-U133 Plus 2.0 arrays 
(Affymetrix Inc.), that contain 54,613 probe sets. The 
arrays were washed and stained with phycoerythrin- 
streptavidin (SAPE) using the Affymetrix Fluidics Station 
450, and the arrays were scanned in the Affymetrix  
GeneArray 3000 scanner to produce raw data image files. 
    Normalization of gene expression values and hierachical 
clustering were performed using dCHIP software (Li and 
Wong, 2001). Transcripts were identified as being diffe-
rentially expressed if the comparison of groups yielded a 
fold change higher than 1.5 (using the 90% lower con-
fidence interval of the fold change), a difference of means 
higher than 50 and a P＜ .05 (two-tailed, two-sample 
unequal variance t-test, Welch test).
Validation by quantitative RT-PCR (QPCR)
QPCR was performed in nine selected genes (based on 
their molecular functions according to Gene Ontology 
Consortium (www.geneontology.org)) in two samples from 
each of the four groups of tissue; lip tissue from CL and 
CLP and palate tissue from CP and CLP: cDNA was 
synthesised with superscript II (RNase H-) reverse trans-
criptase (Invitrogen, Carlsbad, CA) and QPCR analysis 
was performed in a DNA Engine Opticon 2 (Biorad, 
Hercules, CA) using LightCycler FastStart DNA master 
SYBR GreenI kit (Roche, Indianapolis, IN). Primers were 
purchased from TAG Copenhagen (Copenhagen, DK). All 
primers are intron-spanning and designed using Oligo6 
software (Cascade, CO). The identity of PCR products and 
primer sequence specificity was confirmed by BLAST 
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analysis (NCBI, NIH, http://www.ncbi.nlm.nih.gov/ BLAST/) 
and melting curve analyses. Gene expression levels were 
normalised to the expression of β-2-microglobulin pre-
cursor (B2M). Primer sequences (from 5' to 3') were: B2M, 
forward (F)-TGTGCTCGCGCTACTCTCTC, reverse (R)- 
CTGAATGCTCCACTTTTTCAATTCT; BST2, F-GATGGA-
GTGTCGCAATGTCA, R-GCCCAGCAGCACAATCA; SPEN, 
F-GTCCTGGCCCATCGGT, R-TTGGCCTGCAGGTAAGT-
GAT; DIO2, F-AGAGGGACTGCGCTGCGTCT, R- CTGG-
CAGCTGGCTCGTGAAA; CRYAB, F-GTTGGGAGATGTG-
ATTGAGG, R-GCTTCTCTTCACGGGTGAT; PACN3, F-GG-
GTGAGGGCACTCTATGAC, R-GCCCTCAGCCTAGACT-
CGT; EGFL6, F-AGACATTGGCCGATTGAA, R-ATGCCA-
GAGGTCCTATGATG; SPP1 (human), F-CTAAGAAGTTT-
CGCAGACCT, R-CTATCAATCACATCGGAATG; Spp1 (mou-
se), F-TCTGATGAGACCGTCACTGC, R-TCGGAATTTCA-
GATACCTATCATCT; CXCR4, F-TCCAGTAGCCACCGC-
ATCT, R-TGCCCACAATGCCAGTTAAG; AMPD2, F-CTC-
AGCTATCACCGGAATC, R-TCTTTACCTTGTGCGAGAAG. 
Validation by immunohistochemistry
A total of seven human embryos (6th to 8th week) and five 
human fetuses (9th to 11th week) were examined. The 
human embryos and fetuses, which ranged from 7-60 mm 
crown-rump length (CRL), were obtained from spon-
taneous and legal abortions or ectopic pregnancies. Infor-
med consent was obtained. Immediately following the 
operation, the embryos and fetuses were dissected into 
appropriate blocks and fixed for 12 to 24 h at 4oC in one of 
the following fixatives: 10% neutral buffered formalin, 4% 
Formol-Calcium, Lillie's or Bouin's fixatives. The speci-
mens were dehydrated with graded alcohols, cleared in 
xylene and paraffin embedded. Serial sections, 3-5 μm 
thick, were cut in transverse, sagittal or horisontal planes 
and placed on silanized slides. Representative sections of 
each series were stained with hematoxylin and eosin or 
with toluidine blue.
    The paraffin sections from tissue blocks containing the 
craniofacial region (including the palatal shelves) were 
dewaxed, rehydrated and washed in Tris-buffer saline 
(TBS: 0.05 M Tris, 0.15 M NaCl, pH 7.6) with 0.01% 
Nonidet P-40 (TBS/Nonidet)). All sections were incubated 
in 1.5% H2O2 in TBS/Nonidet for 15 min to block 
endogenous peroxidase activity, and then in 10% normal 
goat serum in TBS/Nonidet for 30 min to block non-specific 
binding. Sections were incubated overnight at 4oC with the 
primary antibody, diluted in 10% goat serum. Sections 
were incubated with (1) human monoclonal anti-CXCR4 Ig, 
diluted 1:1500 (RD systems MAB173), (2) rabbit polyclonal 
anti-SPP1 Ig, diluted 1:600 (Abcam ab33046), and (3) 
rabbit polyclonal anti-serglycin Ig, diluted 1:400 (kindly 
provided from the laboratory of Dr. Niels Borregaard, 
(Niemann et al., 2004)).
    The primary antibodies were detected using the peroxi-
dase revelation method (DakoCytomation EnVision+ 
DualLink System), according to the manufacturer's recom-
mendations. As negative controls, sections were incubated 
with only the secondary antibody.
In silico analysis
The Craniofacial and Oral Gene Expression Network 
(COGENE) is a publicly available database, comprising 
gene expression profiles (Affymetrix GeneChip analysis 
and Serial Analysis of Gene Expression (SAGE)) from 
human embryonic craniofacial structures. Our results in 
palate tissue were compared to COGENE Affymetrix 
expression profiles from the following structures, since 
these structures develop into palatal tissue: 4th week 
pharyngeal arch 1, 5th week pharyngeal arch 1, 6th week 
maxilla, and 8.5th week palatine shelves. Expression in lip 
tissue was compared to COGENE Affymetrix expression 
profiles from: 4th week pharyngeal arch 1, 5th week pha-
ryngeal arch 1, 6th week maxilla, 4th week frontonasal 
prominence, 5th week frontonasal prominence, 6th week 
median nasal prominence, and 8.5th week upper lip, as 
these structures develop into lip tissue. A few COGENE 
SAGE profiles were relevant for the lip development: 4th 
week frontonasal prominence, 5th week frontonasal pro-
minence, and 8.5th week upper lip. 
    Signalling pathways were analyzed using a human 
protein interaction network, which we have previously 
constructed using several network databases (Lage et al., 
2007). 
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